There is a great need for the development of noninvasive, highly sensitive, and widely available imaging methods that can potentially be used to longitudinally monitor treatment of Parkinson's disease (PD). Here we report the monitoring of GDNF-induced functional changes of the basal ganglia in hemiparkinsonian monkeys via pharmacological MRI measuring the blood oxygenation level-dependent (BOLD) response to a direct dopamine agonist (apomorphine, APO). After testing BOLD responsiveness to APO in their normal state, two additional scans were taken with the same dose of APO stimulation after induced parkinsonism. Then all animals were chronically treated with GDNF for 18 weeks by a programmable pump and catheter system. The catheter was surgically implanted into the right putamen and connected to the pump via flexible polyurethane tubing. phMRI scans were taken at both 6 and 18 weeks while they received 22.5 µg of GDNF per day. In addition, behavioral changes were monitored throughout the entire study. The primary finding of this study was that APO-evoked activations in the DA denervated putamen were attenuated by the chronic intraputamenal infusion of GDNF accompanied by improvements of parkinsonian features, movement speed, and APO-induced rotation compared to data collected before the chronic GDNF treatment. The results suggest that phMRI methods in combination with administration of a selective DA agonist may be useful for monitoring neurorestorative therapies in PD patients in the future.
INTRODUCTION
study. phMRI has shown the capacity of mapping the nigrostriatal DA system in the nonhuman primate model of PD (8, 39) . For example, Zhang and colleagues (39) Dopamine (DA) plays a pivotal role in Parkinson's disease (PD). This has resulted in attempts to visualize reported for the first time a positive correlation between the BOLD response to d-amphetamine (which evokes its changes in the living brains of PD patients by using various neuroimaging techniques such as positron emis-DA release) and dopaminergic neurons in the substantia nigra pars compacta (SNc) ipsilateral to MPTP (1-sion tomography (PET) with [ 18 F]fluorodopa to measure striatal DA levels and photon emission computed tomethyl-4-phenyl-1,2,3,6-tetrahydropyridine) administration. mography (SPECT) with [ 123 I]IBZM to study DA receptors [for reviews, see (11, 12, 27) ]. The development of Glial cell line-derived neurotrophic factor (GDNF) protects and restores the nigrostriatal dopaminergic syspharmacological MRI (phMRI) has allowed investigators to visualize DA systems in a living brain without tem in rodent and nonhuman primate models of PD (4, 15, 18, 23, 30) . This trophic factor has also shown promise the injection of radioactive tracers. phMRI is based on changes of the blood oxygen level-dependent (BOLD) in phase I clinical trials for the treatment of PD (17, 29) . Ample evidence has proven that GDNF can protect and signal upon a CNS drug challenge (21, 31) . The nonselective DA receptor agonist apomorphine (APO) was promote survival of presynaptic dopaminergic neurons in the SNc and axons in the striatum (15, 36) . used to stimulate postsynaptic DA receptors in this 418 LUAN ET AL.
This pilot study was designed to test the hypothesis MPTP Administration and Behavioral Assessments that phMRI techniques combined with the use of selecAfter baseline data collection, including behavior and tive dopaminergic agonists can be employed to monitor phMRI, the animals received right intracarotid artery intreatment of PD. Specifically, this study was designed fusions of 2.4 mg MPTP per animal (i.e., 0.4 mg/kg for to determine if the amplitude of APO-induced activaa 6-kg animal) to induce continuously expressed unilattions in the MPTP-lesioned putamen can be attenuated eral parkinsonian features contralateral to the affected by chronic GDNF treatment in parkinsonian rhesus brain (3,26). Behavioral tests were not conducted until monkeys. We have previously reported that the majority full and stable PD features had developed. Typically, of APO-induced activations were observed in the this took 2-3 months. The evaluation of parkinsonism MPTP-lesioned striatum due to DA deficiency, which was based on weekly videotaped behavior in the aniresults in increases of sensitivity levels of postsynaptic mal's home cage including bradykinesia, rigidity, pos-DA receptors toward challenges of a DA agonist like ture, balance, and APO-induced rotational behavior. The APO in nonhuman primates (37) . Because APO can divideotapes were evaluated by two well-trained and experectly stimulate supersensitive postsynaptic DA receprienced raters. The interclass correlation of independent tors in the denervated striatum (28) and has been used measurements of parkinsonian features was r = 0.81. In in the clinic for treatment of PD, we believe that the addition to the clinical rating scale, movement speed pharmacological actions of APO can provide informawas also quantified by using the automated video-tracktion on postsynaptic changes in dopaminergic pathways ing system, EthoVision (34) . of the nigrostriatal system. Those changes should be deProcedures for phMRI Scans tectable by phMRI methods based on previous studies (35, 38, 39) .
The phMRI scans were conducted on a Siemens VISION 1.5 T MRI scanner using the body coil to transmit radio frequency and an 8-cm-diameter surface coil MATERIALS AND METHODS placed above the monkey's head for RF signal recepAnimals tion. The anatomical structures of interest were visualized using a 3D FLASH sequence with 1-mm isotropic Three adult female rhesus monkeys (Macaca mulatta) were obtained from a commercial supplier (Coresolution (TR/TE = 21/6 ms, flip angle = 30°, image matrix size = 128 × 128 × 90, field of view = 128 mm). vance, Alice, TX) and were housed in individual cages in a temperature-controlled room and maintained on a
The functional MR images from pharmacological challenges were acquired continuously using a FLASH 2D 12-h light and 12-h dark cycle. Water was available ad libitum. Standard primate biscuits were supplemented multiple gradient-recalled-echo (MGRE) navigator sequence (39) . Slices were acquired interleaved for two daily with fresh fruits and vegetables. The animals' care was supervised by experienced veterinarians and all prononcontiguous coronal sections: the first slice covering the area of the rostral putamen and caudate nucleus, and tocols used in the study were approved by the University of Kentucky's Animal Care and Use Committee.
the second covering the substantia nigra (Fig. 1 ). An 11-echo MGRE sequence was used to map, on a pixel-byAs reported in detail elsewhere (2,38,39), the animals were trained for phMRI scans under full conscious alert pixel basis, the local transverse relaxation rate R 2 *, an intrinsic MRI parameter sensitive to changes in local ceconditions prior to MPTP administration. Briefly, the animals were adapted to an MRI-compatible chair conrebral blood flow and oxygenation associated with changes in cerebral activity (7, 8, (37) (38) (39) . The last TE imstructed from nonferromagnetic materials and designed to comfortably position an adult rhesus monkey within ages were acquired without phase encoding gradients to serve as a navigator echo for detection of head motion the magnet bore in a prone position. Under local anesthesia (1% lidocaine, 1.0 ml on each side), two MRIduring the acquisition of data for a single calculated R 2 * image. The FLASH 2D acquisition parameters were: compatible pins were inserted through the overlying skin and connective tissue to contact the bony cranium. In TR = 250 ms, TE = 7-75 ms, ∆TE = 6.5 ms, image matrix size = 112 × 128, field of view = 128 mm, slice addition, earbars, constructed to follow the natural angle of the rhesus ear canal (10-15°down from horizontal), thickness = 3 mm, flip angle = 40°, bandwidth = 156 Hz/pixel. The changes in response to dopaminergic were fashioned from nylon and secured to the chair's head holder. Inserted into the animal's ears, the ear bars stimulations were averaged spatially across pixels within individual ROIs selected in the caudate nucleus, putaprovided additional restraint to head motion. The ear bars also functioned to reduce the gradient noise during men, GPi, GPe, and substantia nigra (Fig. 1) . The ROI dimensions were 3 × 3 × 3 mm, each representing a 27 phMRI scanning. During training sessions, animals were allowed to watch movies and each session lasted 45-75 mm 3 volume. ROIs were manually selected in both hemispheres of MPTP-lesioned and normal control animin. The entire chair training usually took 2 months. Because of variability in the inherent noise level due to differences in 2). The detailed description for these procedures has been published elsewhere (1,18,19). On weeks 6 and 18 positioning animals for each scan and the movements during scanning, the replicate scans were treated as inposttreatment, phMRI studies were conducted on all animals while receiving 22.5 µg/day GDNF (1,18). dependent observations in the analysis. Some partial volume effects are unavoidable, especially in the Immunohistochemical Staining for GDNF through-slice direction and for smaller structures such as the substantia nigra. To minimize these effects, we used At the conclusion of GDNF intraputamental infusion, multiple animals and each animal underwent two replithe animals were euthanatized by an overdose of pentocate scans using the same protocol. Small, unavoidable barbital followed by transcardial perfusion of 6 L icedifferences in slice placement between the two scans cold saline. The brains were removed, placed in an icehelped to ensure that no systematic errors were commitcold brain mold, and sliced into 4-mm-thick coronal ted in the ROI selection. Prior to the administration of slabs, which were then immersion fixed in 4% paraformapomorphine, a total of 40 image frames were collected aldehyde at 4°C. The sections with the striatum were over 20 min to determine the baseline state. Following injection of APO, an additional 40 frames were collected to track the dynamic response (2,38,39). The change in R 2 * (i.e., ∆R 2 *), which represents the phMRI activation response to drug, was determined as the difference between the mean R 2 * across 20 images postdrug administration during the period of peak response (5-15 min) and the mean R 2 * within the 40 baseline images. A reduction ("negative" change) in R 2 * associated with a local decrease of paramagnetic deoxyhemoglobin is an indicator of a BOLD effect activation (7, 39) .
Catheter/Pump Implantation
Following the baseline imaging in the parkinsonian state, the animals had a multiport catheter implanted in the right putamen using MRI-guided stereotactic procedures. The catheter was connected via flexible polyurethane tubing to a programmable pump (SynchroMed was placed in a pocket of a jacket worn by the monkey. then cut at 40 µm thick and stained immunohitochemically for GDNF (polyclonal antibody, 1:1500; Chemicon International) to examine the diffusion from the catheter.
Statistical Analyses
The behavioral response to APO administration, including changes in parkinsonian ratings and movement speed, was analyzed by two-tailed paired t-tests. For the evaluation of phMRI data, two-sided independent sample t-tests were used to evaluate drug effects in the separate ROIs. The calculation of total mean-squared error includes contributions from within-animal residual variation in the phMRI time-series response data along with variability across replicate scans and between animals. The analysis is described in more detail elsewhere (2,38, 39). In all tests, a value of p < 0.05 was considered significant.
RESULTS
All animals expressed stable, unilateral parkinsonian features from the eighth week post-MPTP administration, including bradykinesia, rigidity of the left upper and lower limbs, stooped posture, and balance instabilities. These parkinsonian features were significantly improved except for posture by 0.1 mg/kg APO treatment (Fig. 3, filled columns) . Additionally, APO-induced counterclockwise rotational behavior (turning toward MPTP lesioned side) was observed in all animals.
No complications were encountered during catheter implantation into the putamen in any of the animals. Also, no adverse effects were observed following the surgery or during chronic GDNF treatment. While a steady improvement was evident post-GDNF delivery, there was an average of 22% improvement in the motor functions as per the nonhuman primate parkinsonian rating scale by the sixth week of the treatment (Fig. 4A) , which was maintained up to 18 weeks. The improvements in motor function were also evident from increased movement speed (Fig. 4B) . The improvements seemed to parallel the parkinsonian rating scale. Further- As previously reported (39) , while little changes were phMRI MONITORING OF TREATMENT FOR PD 421 found in the putamen and caudate nucleus prior to MPTP treatment (Fig. 5A) , strong APO-induced activations were seen in the same regions on the ipsilateral side of MPTP administration (Fig. 5B, Fig. 7A ). As predicted, chronic intraputamenal infusion of GDNF not only significantly improved motor function but also reduced the APO-induced activation in the putamen on the ipsilateral side to GDNF infusion at the sixth and 18th week compared to the data collected prior to GDNF treatment. The BOLD activations were significantly reduced at both 6 and 18 weeks after the treatment, falling much closer to the baseline levels in DA denervated putamen (Fig. 6A) . However, GDNF-induced functional changes in the caudate nucleus seemed to be biphasic (i.e., APO-induced activation was slightly higher at the sixth week and significantly decreased at the 18th week posttreatment) (Fig. 6B) ). There was little change in BOLD signal in the SN (data not shown). Typical changes of BOLD signal in response to GDNF treatment are shown in Figure 7 (monkey #445). The BOLD effect Figure 6 . Average ∆R 2 * for right rostal putamen (A) and right caudate nucleus (B). Intraputamenal GDNF administration decreased APO-evoked activation in the putamen, with the responses measured at 6 and 18 weeks. The responses in the caudate nucleus appeared to be biphasic, with activation increasing at 6 weeks and decreasing to more normal levels by 18 weeks of treatment. *p < 0.05; **p < 0.01. was superimposed on a T1-weighted image from the same monkey collected on the same day. The size of APOevoked activation was significantly reduced compared with data collected before chronic GDNF treatment.
Postmortem analysis showed the radius of diffusion from the catheter. Positive GDNF staining was observed in most of the treated putamen (Fig. 8) . The spread of GDNF along the catheter track was seen in all monkeys with a diffusion radius of at least 3 mm at the tip of the catheter.
DISCUSSION
The primary finding of this study was that APOevoked activations in the DA denervated putamen were attenuated by the chronic intraputamenal infusion of useful for monitoring neurorestorative therapies in PD study were as follows: 1) it has been previously demonstrated that phMRI can specifically detect APO-induced patients in the future.
The reasons for specifically selecting APO for stimuactivations in the parkinsonian rhesus brain (39), and 2) APO has been widely used as a DA agonist in animal lating the dopaminergic nigrostriatal system for this research for three decades. For example, in unilateral 6-hydroxydopamine-lesioned rats, a standard rodent model of PD, APO challenge has been used as a method to assess the severity of lesions judged by the number of turns toward the lesioned side (33) . The rotational behavior could also be improved by GDNF in rats (14, 22) . Finally, APO is also widely used in the clinic, especially to treat levodopa-induced motor complications [for reviews see (20, 25) ]. GDNF has been proven to halt or reverse progressive degeneration of the nigrostriatal DA system in models of PD (5, 9, 15, 16, 18, 23, 32) . Results from these studies suggest that the most likely mechanism is through the trophic effects of GDNF on midbrain DA neurons. Denervations of nigrostriatal DA levels will lead to an increased sensitivity of DA receptors to the challenge of DA agonists such as APO (33) . Grondin and colleagues (18) demonstrated that GDNF could partially restore dopaminergic functions with chronic intraputamenal infusion of GDNF. They found that infusion of GDNF at 15 µg/day, induced >20% bilateral increases in the number of nigral cells and >75% bilateral increases in dopamine metabolites levels in the striatum. In addition, the DA levels increase more than twofold in the periventricular Levodopa has been a "gold standard" for treatment there appears to be a discrepancy between current imaging protocols and clinical outcomes. In a National Inof PD since it was introduced more than 30 years ago because it provides marked symptomatic benefits to virstitute of Health sponsored randomized double-blind study on PD patients receiving either fetal tissue transtually all PD patients and improves their daily living (35) . Although the drug is extremely effective, few studplants or sham surgery, a 40% increase in [ 18 F]dopa uptake in the putamen contrasted with a modest (nonsignifies have been done to detremine whether therapeutic and potential toxic effects of the drug can be noninvasively icant) 18% improvement in the mean unified Parkinson's disease rating scale (UPDRS) in one study involving 40 and longitudinally monitored by neuroimaging methods in animal models of the disease. Recently, the relationpatients. In a second study involving 34 patients, a 20-30% increase of [ 18 F]dopa uptake was seen in the striaship between the magnitude of APO-induced pharmacological responses and the behavioral response to levotum, but clinical changes failed to reach statistical significance [for a review see (6)]. Most recently, a dopa treatment were reported in parkinsonian rhesus monkeys (39) . In detail, stronger activations were seen significant increase was found in [
18 F]dopa uptake in the putamen of PD patients receiving trophic factor therapy, in animals that were less responsive to levodopa treatment. More interestingly, the histological analyses rewhile clinical improvements did not differ significantly from the control group (24) . We believe that phMRI vealed that the monkeys with less responsiveness to levodopa treatment had fewer dopaminergic neurons in the methods may face the similar issues in the future.
In this proof-of-concept study, phMRI showed its poSNc (39) . These results suggest a link between the phMRI signal and responsiveness to treatment. The abiltential to be used for monitoring treatments in PD by its capability of detecting functional changes before and ity to reliably monitor, in a noninvasive and longitudinal manner, therapeutic effects would provide valuable inafter the chronic intraputamenal infusion of the neurotrophic factor, GDNF. The changes in phMRI signals formation in assessing the progression of PD and the effects of treatment over time. Indeed, results from were accompanied by improvements in motor functions and APO-induced rotations. The results from this study many imaging studies have demonstrated the possibility of using neuroimaging methods to monitor therapeutic combined with our previous findings (39) suggest that phMRI methods could possibility be used for early deeffects in humans (6,17,24). For example, Gill et al. reported that chronic infusion of GDNF in PD patients tection of functional changes in the nigrostriatal system and for longitudinally monitoring of treatments for PD produced a 28% increase of [ 18 F]dopa uptake around the tip of the infusion catheter after 18 months (17) , which in humans. suggests that an increase of DA storage occurred after
